Mats JÃ¶nsson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4326111/publications.pdf

Version: 2024-02-01

22	694	567281 15	713466 21
papers	citations	h-index	g-index

23	23	23	1898
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A gene expressionâ€based single sample predictor of lung adenocarcinoma molecular subtype and prognosis. International Journal of Cancer, 2021, 148, 238-251.	5.1	10
2	Detection of Non-Small Lung Cell Carcinoma-Associated Genetic Alterations Using a NanoString Gene Expression Platform Approach. Methods in Molecular Biology, 2021, 2279, 91-107.	0.9	0
3	Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune-evasion mechanisms. Nature Cancer, 2021, 2, 1224-1242.	13.2	37
4	Analysis of human papillomaviruses and human polyomaviruses in lung cancer from Swedish never-smokers. Acta OncolÃ³gica, 2020, 59, 28-32.	1.8	4
5	Clinical Utility of Targeted Sequencing in Lung Cancer: Experience From an Autonomous Swedish Health Care Center. JTO Clinical and Research Reports, 2020, 1, 100013.	1.1	4
6	Comprehensive analysis of RNA binding motif protein 3 (RBM3) in nonâ€small cell lung cancer. Cancer Medicine, 2020, 9, 5609-5619.	2.8	10
7	Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence. Acta OncolÃ³gica, 2019, 58, 1079-1086.	1.8	18
8	A combined gene expression tool for parallel histological prediction and gene fusion detection in non-small cell lung cancer. Scientific Reports, 2019, 9, 5207.	3.3	17
9	Immunoprofiles of colorectal cancer from Lynch syndrome. OncoImmunology, 2019, 8, e1515612.	4.6	14
10	Molecular subtype classification of urothelial carcinoma in Lynch syndrome. Molecular Oncology, 2018, 12, 1286-1295.	4.6	25
11	Gene Expression Profiling of Large Cell Lung Cancer Links Transcriptional Phenotypes to the New Histological WHO 2015 Classification. Journal of Thoracic Oncology, 2017, 12, 1257-1267.	1.1	43
12	Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer. Oncotarget, 2017, 8, 34796-34810.	1.8	45
13	CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma. PLoS ONE, 2017, 12, e0186284.	2.5	26
14	Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. BMC Urology, 2016, 16, 15.	1.4	52
15	Mutational and gene fusion analyses of primary large cell and large cell neuroendocrine lung cancer. Oncotarget, 2015, 6, 22028-22037.	1.8	61
16	Global Transcriptional Changes Following Statin Treatment in Breast Cancer. Clinical Cancer Research, 2015, 21, 3402-3411.	7.0	44
17	Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. Urology, 2015, 86, 1212-1217.	1.0	74
18	Genome-wide DNA Methylation Analysis of Lung Carcinoma Reveals One Neuroendocrine and Four Adenocarcinoma Epitypes Associated with Patient Outcome. Clinical Cancer Research, 2014, 20, 6127-6140.	7.0	91

#	ARTICLE	IF	CITATIONS
19	Molecular Subtyping of Serous Ovarian Tumors Reveals Multiple Connections to Intrinsic Breast Cancer Subtypes. PLoS ONE, 2014, 9, e107643.	2.5	17
20	Immunohistochemistry in the Differential Diagnostics of Primary Lung Cancer. American Journal of Clinical Pathology, 2013, 140, 37-46.	0.7	56
21	Distinct Gene Expression Signatures in Lynch Syndrome and Familial Colorectal Cancer Type X. PLoS ONE, 2013, 8, e71755.	2.5	28
22	Experiences from treatment-predictive KRAS testing; high mutation frequency in rectal cancers from females and concurrent mutations in the same tumor. BMC Clinical Pathology, 2009, 9, 8.	1.8	17